LivaNova (NASDAQ:LIVN) Director Sells $187,266.00 in Stock

Posted by Brian Himes on Sep 8th, 2026

LivaNova PLC (NASDAQ:LIVN – Get Free Report) Director Brooke Story sold 2,300 shares of the firm’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $81.42, for a total value of $187,266.00. Following the sale, the director directly owned 7,488 shares in the company, valued at approximately $609,672.96. This represents a 23.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

LivaNova Price Performance

Shares of LivaNova stock traded down $1.22 during trading hours on Tuesday, hitting $80.70. The company’s stock had a trading volume of 472,956 shares, compared to its average volume of 755,599. The business has a 50 day moving average price of $80.67 and a two-hundred day moving average price of $73.05. LivaNova PLC has a 12-month low of $48.82 and a 12-month high of $85.76. The company has a market cap of $4.45 billion, a PE ratio of 23.88 and a beta of 0.87. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.45.

LivaNova (NASDAQ:LIVN – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $1.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.17. The firm had revenue of $390.59 million during the quarter, compared to analysts’ expectations of $380.50 million. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The firm’s revenue was up 10.8% on a year-over-year basis. During the same quarter last year, the business posted $1.05 earnings per share. Analysts expect that LivaNova PLC will post 3.77 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LIVN has been the topic of several research analyst reports. Zacks Research cut shares of LivaNova from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Stifel Nicolaus set a $85.00 target price on LivaNova in a report on Wednesday, August 5th. Freedom Capital upgraded LivaNova to a “hold” rating in a research report on Tuesday, June 30th. KeyCorp increased their price target on LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, June 22nd. Finally, Mizuho raised their price target on LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Six research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $84.12.

Read Our Latest Report on LIVN

Institutional Trading of LivaNova

Institutional investors and hedge funds have recently modified their holdings of the stock. Allworth Financial LP lifted its position in shares of LivaNova by 93.5% in the 2nd quarter. Allworth Financial LP now owns 298 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of LivaNova during the second quarter valued at approximately $4,053,000. California State Teachers Retirement System increased its holdings in LivaNova by 7,996.3% during the second quarter. California State Teachers Retirement System now owns 5,154,505 shares of the company’s stock valued at $423,855,000 after buying an additional 5,090,840 shares during the period. Turner Financial Group Inc. purchased a new position in LivaNova during the second quarter valued at approximately $392,000. Finally, Public Employees Retirement System of Ohio bought a new position in LivaNova in the second quarter worth approximately $37,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

(Get Free Report)

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.